Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.
NCT03220230
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Female or male, 18 years of age or older.
- Patients with histologically or cytological proven diagnosis of NSCLC, pathologically identified as adenocarcinoma.
- Patient naïve in lung cancer treatment
- Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the study prior to enrollment.
- Patients must give consent to the research use of their archived or tumor FFPE tissue, and if available, 2 blood tubes.
- Prior chemotherapy treatment.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Birmingham, Alabama
- Birmingham, Alabama
- Birmingham, Alabama
- Greenbrae, California
- San Fransisco, California
- San Mateo, California
- San Pablo, California
- Tampa, Florida
- Chicago, Illinois
- Chicago, Illinois
- Park Ridge, Illinois
- Skokie, Illinois
- Jefferson, Indiana
- Crestview Hills, Kentucky
- LaGrange, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Boston, Massachusetts
- Boston, Massachusetts
- Ann Arbor, Michigan
- Ann Arbor, Michigan
- New York, New York
- Durham, North Carolina
- Cincinnati, Ohio
- Cincinnati, Ohio
- Cincinnati, Ohio
- Columbus, Ohio
- Philadelphia, Pennsylvania
- Nashville, Tennessee
- Nashville, Tennessee
- Houston, Texas
- Salt Lake City, Utah
- Chippewa Falls, Wisconsin
- Eau Claire, Wisconsin
- Ladysmith, Wisconsin
- Marshfield, Wisconsin
- Marshfield, Wisconsin
- Minocqua, Wisconsin
- Rice Lake, Wisconsin
- Stevens Point, Wisconsin
- Wausau, Wisconsin
- Wisconsin Rapids, Wisconsin
- Woodruff, Wisconsin
- Edmonton, Alberta
- Montreal, Quebec
- Gauting,
- Grosshansdorf,
- Heidelberg,
- Cork,
- Dublin,
- Bologna,
- Orbassano (Torino),
- Amsterdam, NH
- Hospitalet de Llobregat, Barcelona
- Glasgow,
- London,
- Greenbrae, California
- San Mateo, California
- San Pablo, California
- Tampa, Florida
- Covington, Louisiana
- Metairie, Louisiana
- Metairie, Louisiana
- New Orleans, Louisiana
- Boston, Massachusetts
- Stony Brook, New York
- Philadelphia, Pennsylvania
- Gallatin, Tennessee
- Hermitage, Tennessee
- Lebanon, Tennessee
- Murfreesboro, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Smyrna, Tennessee
- Poway, California
- Washington, District of Columbia
- Tampa, Florida
- New York, New York
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title | Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients. | ||||||
Official Title | NON INTERVENTIONAL MULTICENTER STUDY, FOR THE VALIDATION OF MOLECULAR DIAGNOSTIC TECHNOLOGIES IN SUBJECTS WITH NON SMALL CELL LUNG CANCER (NSCLC) PROTOCOL N° X9001083 | ||||||
Brief Summary | This is a non-interventional multi-center with investigational sites in Chile and Brasil diagnostic study to validate novel diagnostic technologies, such as Next Generation Sequencing (NGS) from both tissue and blood compared to the current gold standard. As a non-interventional study, patients will receive the treatment indicated by their doctor independently of their participation on this study. Many cancer cells look the same under the microscope. But as these cells are studied at the molecular level, some genetic alterations or defects that are more common to certain types of cancer are identified. In some cases, these defects are what make the cells grow and multiply abnormally. Biomarkers are the molecular fingerprints of these genetic defects. By testing a sample of your tumor for biomarkers, doctors can learn if your cancer has one of these defects, and that may point to a specific treatment choice. One of the genetic biomarkers that are believed to cause some cancers to grow is the ALK fusion gene. About 3% to 5% of people with NSCLC may test positive for ALK. ROS1 is a receptor found in 1 to 2% of people with this type of cancer. The present study is designed to advance the molecular testing methodologies to identify ALK+ and ROS1+ NSCLC patients. A positive correlation with these new technologies will mean an efficient, more accurate diagnostic test, which could impact a greater number of cancer patients around world. | ||||||
Detailed Description | B. Lung Cancer Non-small cell lung cancer (NSCLC) is a common cause of cancer mortality throughout the world. In 2007, there were 1.5 million new lung cancer cases diagnosed worldwide, including around 733,100 cases in the South American Region.6 Approximately 85% of lung cancer is histologically defined as non small cell and the remaining 14% as small cell. The majority of patients with NSCLC present with inoperable locally advanced (Stage IIIB) or metastatic (Stage IV) disease for which no curative treatment is yet available. In newly diagnosed patients with good performance status, platinum based doublet-combination chemotherapies are associated with a median overall survival (OS) of 7.4 to 9.9 months. 7, 8, 9, 10, 11, 12 Therefore, newer agents with novel mechanisms of action are still desperately needed for this serious life-threatening disease. 15,16 The rapid and efficient identification of key driver genes in non-small-cell lung cancer (NSCLC) is becoming increasingly important.17 Clinical screening efforts have revealed that the most common mutations in lung cancer specimens involve EGFR and KRAS, along with 10 other genes that show a prevalence of mutation in 5% or less of tumors. The ALK gene is rearranged in around 3%-5% of patients with NSCLC and has been the focus of intense basic and clinical research, suggesting that the frequency of the gene rearrangement is similar in Asian and Western patients. ROS1 is a receptor tyrosine kinase of the insulin receptor family. Chromosomal rearrangements involving the ROS1 gene were originally described in glioblastomas, where ROS1 (chromosome 6q22) is fused to the FIG gene (chromosome 6q22 immediately adjacent to ROS1), 16 and have been shown to be transforming in transgenic mice.17 More recently, ROS1 fusions were identified as potential driver mutations in an NSCLC cell line (HCC78; SLC34A2-ROS1) and an NSCLC patient sample (CD74-ROS1). 18 These fusions led to constitutive kinase activity and were associated with sensitivity in vitro and in vivo to crizotinib. As of December 2013, 16 different variants have been found.16, 17, 18 The present study is designed to advance the molecular testing methodologies to identify ALK+ and ROS1+ NSCLC patients. Advanced next generation sequencing screening methodologies will be used to identify NSCLC patients whose tumors contain a ROS1 gene inversion or translocation or an ALK translocation. A parallel test for ALK+ by either the Abbott ALK FISH test or the Ventana ALK IHC test is necessary to validate the NGS test in all samples. A parallel test for ROS1+ by either the Kreatech FISH test or the D4D6 ROS1 IHC test may be necessary to validate the NGS test in all samples. | ||||||
Study Type | Observational | ||||||
Study Design | Observational Model: Cohort Time Perspective: Cross-Sectional | ||||||
Target Follow-Up Duration | Not Provided | ||||||
Biospecimen | Retention: Samples With DNA Description: tumor tissue whole blood | ||||||
Sampling Method | Non-Probability Sample | ||||||
Study Population | Lung cancer patients. | ||||||
Condition | Lung Neoplasms | ||||||
Intervention | Not Provided | ||||||
Study Groups/Cohorts | Not Provided | ||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status | Completed | ||||||
Actual Enrollment | 4240 | ||||||
Original Estimated Enrollment | 6000 | ||||||
Actual Study Completion Date | October 30, 2018 | ||||||
Actual Primary Completion Date | October 30, 2018 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| ||||||
Sex/Gender |
| ||||||
Ages | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers | No | ||||||
Contacts | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries | Brazil, Chile, Peru | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number | NCT03220230 | ||||||
Other Study ID Numbers | X9001083 NIRVANA ( Other Identifier: Alias Study Number ) | ||||||
Has Data Monitoring Committee | No | ||||||
U.S. FDA-regulated Product |
| ||||||
IPD Sharing Statement |
| ||||||
Responsible Party | Pfizer | ||||||
Study Sponsor | Pfizer | ||||||
Collaborators | Not Provided | ||||||
Investigators |
| ||||||
PRS Account | Pfizer | ||||||
Verification Date | October 2019 |